Implementing The Trump Administration's America First Global Health Strategy In Angola

robot
Abstract generation in progress

(MENAFN- U.S. Department of State)

Today, the United States and the Republic of Angola signed a five-year bilateral health cooperation Memorandum of Understanding (MOU), advancing the Trump Administration’s America First Global Health Strategy in Africa.

Working with Congress, the Department of State intends to provide $71 million to support HIV, malaria, and global health security programming, while Angola will invest $50 million-with 30 percent dedicated to essential laboratory and health commodities. The MOU promotes private sector integration, leveraging both U.S. companies and Angolan to strengthen health systems in human resources, data management, and supply chains.

Additionally, the MOU includes $5 million in global health security funding to strengthen laboratory capacity, especially in remote, underserved areas, enabling Angola to better and more rapidly detect and respond to potential pathogens of concern before they can spread to the United States. The $121 million bilateral health cooperation will advance shared health priorities and strengthen Angola’s path toward health care independence.

America First Global Health Strategy Memoranda of Understanding (MOUs) signed so far represent more than $20.5 billion in new health funding including more than $12.7 billion in U.S. assistance alongside $7.8 billion in co-investment from recipient countries, building on decades of progress fighting HIV/AIDS, malaria, tuberculosis, and other infectious diseases around the world. As of March 19, the State Department has signed 27 bilateral global health MOUs with Angola, Botswana, Burkina Faso, Burundi, Cameroon, Côte d’Ivoire, the Democratic Republic of the Congo, the Dominican Republic, El Salvador, Eswatini, Ethiopia, Guatemala, Guinea, Honduras, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mozambique, Niger, Nigeria, Panama, Rwanda, Senegal, Sierra Leone, and Uganda.

MENAFN19032026004514009831ID1110884458

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin